Integrating costimulatory agonists to optimize immune-based cancer therapies.
about
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasA therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.Advances in targeting cell surface signalling molecules for immune modulationCD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomasCostimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
P2860
Integrating costimulatory agonists to optimize immune-based cancer therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Integrating costimulatory agonists to optimize immune-based cancer therapies.
@en
Integrating costimulatory agonists to optimize immune-based cancer therapies.
@nl
type
label
Integrating costimulatory agonists to optimize immune-based cancer therapies.
@en
Integrating costimulatory agonists to optimize immune-based cancer therapies.
@nl
prefLabel
Integrating costimulatory agonists to optimize immune-based cancer therapies.
@en
Integrating costimulatory agonists to optimize immune-based cancer therapies.
@nl
P2093
P2860
P356
P1433
P1476
Integrating costimulatory agonists to optimize immune-based cancer therapies.
@en
P2093
Amy K Wesa
Angela D Pardee
Walter J Storkus
P2860
P304
P356
10.2217/1750743X.1.2.249
P577
2009-03-01T00:00:00Z